Table 1.
Comparison of HPV vaccines.
| HPV Vaccines | Cervarix | Gardasil | Gardasil 9 | |
|---|---|---|---|---|
| Time of FDA Approval | 2009 | 2006 | 2014 | |
| Manufacture | GSK | Merck & Co | Merck & Co | |
| VLP Types | 6 | - | 20 µg | 30 µg |
| 11 | - | 40 µg | 40 µg | |
| 16 | 20 µg | 40 µg | 60 µg | |
| 18 | 20 µg | 20 µg | 40 µg | |
| 31 | - | - | 20 µg | |
| 33 | - | - | 20 µg | |
| 45 | - | - | 20 µg | |
| 52 | - | - | 20 µg | |
| 58 | - | - | 20µg | |
| Expression system | Baculovirus -Insect Cell | Yeast | Yeast | |
| Adjuvant | 50 µg MPL absorbed on 500 µg aluminum hydroxide (AS04) | 225 µg aluminum hydroxyphosphate sulfate | 500 µg aluminum hydroxyphosphate sulfate | |
| Dose | 0.5 mL/dose | 0.5 mL/dose | 0.5 mL/dose | |
| Injection schedule | 0, 1, 6 months | 0, 2, 6 months | 0, 2, 6 months | |
| Cervical cancer Protection rate | 70% | 70–75% | 90% | |